Background
Identification and characterization of circulating serotypes and genotypes of influenza viruses can assist detection of viral antigenic drifts and shifts -phenomena that underlie epidemics and pandemics. 1 Influenza surveillance also allows for the identification and selection of appropriate virus components for inclusion in the annual formulation of influenza vaccines. 2, 3 The recent emergence of novel, highly virulent H5N1 influenza A subtype has heightened global concern about the onset of an influenza pandemic. [4] [5] [6] In response, influenza monitoring and pandemic preparedness are being implemented globally. [7] [8] [9] Despite strong anecdotal evidence of frequent acute upper respiratory infections, sub-Saharan Africa has not conducted influenza surveillance. To begin to address this, a partnership between the US Army Medical Research Unit-Kenya, Kenya Medical Research Institute (KEMRI), Kenya Ministry of Health and the Centers for Disease Control and Prevention-Kenya was established to undertake influenza surveillance activities in Kenya, under the World Health Organization's (WHO) global influenza surveillance program. 2, 3 In this report, we present genetic analysis data of the initial nine influenza A isolates, all belonging to the H3N2 subtype.
Materials and methods

Collection of clinical samples and influenza virus isolations
The following hospitals comprised the active surveillance field sites: Mbagathi, New Nyanza, Malindi, Isiolo, Mombasa Port Reitz, and Kericho ( Figure 1 ). Study sites were selected based on geographic regions and population demographics.
Patients over 2 months of age and presenting at hospital outpatient clinics with fever ( ‡38°C) and either cough or sore throat were recruited by dedicated project Clinical Officers. Subjects with exudative pharyngitis or tonsillitis or symptom onset >72 hours were excluded from enrollment. None of the patients sampled had previously been vaccinated against influenza. Informed consent and assent approved by the KEMRI and the Walter Reed Army Institute of Research institutional review boards was obtained from all participating patients. Patients' age, sex, occupation, residence, workplace, history of influenza-like illness within household, travel history, and animal contact were ascertained and a clinical examination completed.
Duplicate nasopharyngeal samples were collected using a cotton swab and placed in a 1 ml cryovial containing virus transport medium, kept at 4°C, and stored in a liquid nitrogen dry shipper within 8 hours of collection. All samples were transported from the surveillance sites to the National Influenza Center (NIC) laboratory within one week. The cold chain was maintained throughout. Specimens were received weekly and tested for both influenza A and B.
Virus isolation
Influenza virus isolations were performed at the NIC located at KEMRI Nairobi Kenya, using Madin-Darby canine kidney (MDCK) cells. Serotyping was performed by hemagglutination inhibition assay (HAI) using guinea pig red blood cells and reference antiserum in accordance with Centers for Disease Control and Prevention (CDC) protocols. 10 Briefly, inoculated cells were incubated at 37°C with 5% CO 2 for 10 days to allow development of cytopathic effects (CPE). Supernatant fluid was collected from MDCK cultures showing CPE and the hemagglutination titer determined. 10 Subsequent HAI testing was only performed on specimens showing high titers of virus. Isolates with low hemagglutination titers were passaged further in MDCK cells. The guinea pigs used to provide blood for HA and HAI assays were reared under animal care in accordance with KEMRI guidelines.
Polymerase chain reaction
Isolates were sent to the Air Force Institute of Operational Health (AFIOH), San Antonio, TX where they were genotyped. 11, 12 Isolates confirmed at AFIOH were forwarded to the WHO Influenza Collaborating Centre at CDC, Atlanta, USA.
RNA was extracted from 48-hour shell vial cultures at AFIOH using the M48 BioRobot and Mag Attract Virus Mini M48 Kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturers' protocols. For RT-PCR, the hemagglutinin-1 (HA1) gene forward primer designated H3-F7 (5¢-ACTATCATTGCTTTGAGC-3¢) and the reverse primer H3R-1184 (5¢-ATGGCTGCTTGAGTGCTT3¢) were used. The reaction consisted of 5 ll RNA, 400 nmol ⁄ l of each of the primers and the master mixture containing buffer and enzymes following the Superscript III One-Step RT-PCR protocol from the manufacturer (Invitrogen, Carlsbad, CA, USA). The thermocycling conditions included 40 cycles of 94°C for 15 seconds, 52°C for 30 seconds, and 68°C for 75 seconds, with a final extension cycle at 68°C for 5 minutes. All PCR products were purified and sequenced using the Big Dye Terminator v3AE1 Kit (Applied Biosystems, Foster City, CA, USA). The sequencing primers included the H3-F7 and H3R-1184 primers and two internal primers designated as H3R-466 (5¢-GGTGCAACCAATTCAATC-3¢) and H3F-282 (5¢-CAGCAACTGTTACCC-3¢).
HA1 nucleotide sequencing and genetic analyses
Nucleotide sequencing was performed and analyzed using an ABI 3130xl Genetic Analyzer (Applied Biosystems) according to the manufacturers' specifications. Nucleotide contigs were assembled using the Contig Assembly program of Bioedit. 13 Protein translations were performed using DS Gene version 1.5 (Accelrys Inc., Cambridge, UK). Multiple sequence alignments were performed with muscle version 3.6.
14 Phylogenetic analyses were performed with the mega version 3.1.
15 Three-dimensional HA protein structures were generated using Swiss Model 16, 17 and visualized and annotated by the rasmol version 2.7.3. 18, 19 The predicted amino acid (aa) sequences for the 2006-2007 Kenya isolates were submitted to GenBank under accession numbers ABM98421.1, ABM98422.1, ABW34445.1, ABW34446.1, ABW34450, ABS00300, ABS00301, ABS00302, and ABS00303.
Results
A total of 1014 nasopharyngeal specimens were obtained from patients with influenza like illness at outpatient clinics of the six hospitals during the first 9 months of the surveillance program. Although the ages of the subjects ranged from 2 months to 36 years, most (82AE8%) were below 5 years of age and 519 (51%) were male. None were previously vaccinated against influenza. Nine specimens (0AE9%) tested positive for influenza A (H3N2) by isolation. The first four influenza A isolates designated as A ⁄ Nairobi The tree was produced using Neighbor Joining (NJ) method generated by mega 3.1 software. 15 The phylogeny test was done by
Bootstrap based on 500 replications. The accession numbers corresponding to the protein sequences are given by the gi numbers. The year for each southern hemisphere vaccine strain is indicated on the branches. To better understand the immunologic and epidemiologic relevance of the unique aa substitutions observed in the 2006 Kenya isolates, we used the predicted aa sequence of one of the 2006 isolates to develop a 3D model of the HA protein, based on the X-ray crystal structural coordinates of protein precursor; 1HA0. 20 This 3D model revealed that four of the six novel aa substitutions present in the 2006 Kenya isolates occupied immunodominant sites of the HA protein (Figure 4) . 21 Thus, the V112I substitution was located at site E, K173E at site D, S199P immediately adjacent to site B, and N278K adjacent to site C of the HA protein ( Figure 4 ).
Discussion
Kenya and most of Africa have not provided the much needed information on circulating influenza A subtypes and their variants in the region for the purpose of vaccine production, and monitoring trends in virus spread and mutations. In this report, the first characterization of human influenza A viruses from East Africa, we demonstrate prevalence of the H3N2 subtypes, in agreement with data from the rest of the world. In addition, the findings show key aa changes exhibited by the 2006 Kenyan isolates indicating that these viruses were more closely related to recent WHO vaccine strains than to older strains, mirroring the evolution of circulating influenza A globally Six of the 30 aa substitutions identified in the Kenyan viruses were unique and located within known antibodybinding sites. These changes, including V112I and K173E substitutions at site D, S199P at site B, and N278K at site C have also been observed in viruses from Ukraine (internal WHO-share document) and represent a novel genetic variant different from the current vaccine strains. Whereas mutations at dominant sites are believed to be the evolutional outcome of constant immunological and environmental pressures on the viruses, they also represent a public health threat of possible emergence of more virulent isolates that are not covered by available vaccines. More specifically, the V112I change at site E may result in a conformational change on the HA molecule to expose novel epitopes, the substitution at position 173 is within site D that converts a basic R group (K) to an acidic (E) one. This substitution can alter electrostatic properties of the HA molecule to abrogate the binding of antibodies that previously recognized the epitope at site D. Similarly, the asparagine to lysine change at position 278, at site C which is the hinge separating the globular receptor head from the stem of the HA1 protein likely results in an electrostatic changes that alter antigenicity. In contrast, the 3D modeling suggests that the S199P substitution at position 199 of site B did no result in notable conformational change of the HA protein. Such findings emphasize the importance of continuous molecular surveillance and characterization of emerging influenza drift variants in sub-Saharan Africa.
Although the 2006 Kenyan isolates had 100% aa sequence identity at HA1 protein, they had disparate antigenic profiles by hemagglutination inhibition using the A ⁄ Hiroshima ⁄ 52 ⁄ 2005 (H3N2) reference antisera. This antigenic difference may have been induced by genetic and antigenic variation in the other surface proteins such as the neuraminidase, HA2 and M2 proteins known to contribute to antigenic ⁄ immunologic properties of influenza viruses. [22] [23] [24] Work to characterize these other surface glycoproteins is ongoing.
The phylogenetic analysis indicates that the Kenyan isolates are the result of point mutational drift from the A ⁄ California ⁄ 7 ⁄ 04 and A ⁄ Wisconsin ⁄ 67 ⁄ 05 vaccine strains. Although genetically distinct, the 2006 Kenyan isolates were antigenically similar to the 2005-2006 vaccine strains, implying that vaccination with either the northern or southern hemisphere influenza vaccines were protective for local residents and travelers to the region against seasonal influenza viruses.
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